NCT02511795 - AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

August 6, 2015

Primary Completion Date

April 25, 2019

Study Completion Date

October 16, 2019

Conditions

Refractory Solid TumoursRelapsed Small Cell Lung Cancer (SCLC)

Interventions

DRUG

AZD1775

"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."

DRUG

Olaparib

"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."

Trial Locations (6)

10033

Research Site, New York

34232

Research Site, Sarasota

37203

Research Site, Nashville

77030

Research Site, Houston

80218

Research Site, Denver

M5G 2M9

Research Site, Toronto